Avacta is slated to present the final Phase Ia dose escalation data for our lead program, faridoxorubicin. This will be at ESMO 2025 in Berlin, a little bit later next month in October of 2025. There, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback